Therapeutic advances in ankylosing spondylitis

Bibliography

• WOLLHEIM FA: Ankylosing spondylitis. In: Textbook ofRheumatology. Kelley WN, Harris ED, Ruddy S (Eds.), Saunders, Philadelphia, USA (1993):943–955.
   Google Scholar
• RAMOS-REMUS C, RUSSEL AS: Clinical features andmanagement of ankylosing spondylitis. Curr. Opin. Rheumatol. (1993) 5 (4) :408–413.
   PubMedGoogle Scholar
• TOIVANEN A, TOIVANEN P: Epidemiologic, clinical andtherapeutic aspects of reactive arthritis and ankylosing spondylitis. Curr. Opin. Rheumatol. (1995) 7 (4) :279–283.
   PubMedGoogle Scholar
• VAN DER LINDEN S, VAN DER HEIDJE D: Ankylosingspondylitis. Clinical features. Rheum. Dis. Clin. North Am. (1998) 24(4):663–676.
   PubMed Web of Science ®Google Scholar
• VAN DER LINDEN S, VALKENBURG HA, CATS A: Evalua-tion of the diagnostic criteria for ankylosing spondy-litis. A proposal for modification of the New York criteria. Arthritis Rheum. (1984) 27 (4):361–368.
   PubMed Web of Science ®Google Scholar
• CALIN A: Terminology, introduction, diagnosticcriteria and overview. In: The Spondylarthritides. Calin A, Taurog JD (Eds.), Oxford University Press, Oxford, UK (1998):1–15.
   Google Scholar
• BRAUN J, BOLLOW M, NEURE L et al.: Use of immunohis-tologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. (1995) 38 (4) :499–505.
   PubMed Web of Science ®Google Scholar
• •A study demonstrating the presence of T-cells, macrophages and a high amount of TNF-a messenger RNA in the sacroiliac joints of AS patients.
   Google Scholar
• BROWN MA, KENNEDY LG, MACGREGOR AJ et al.: Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA and the environment. Arthritis Rheum. (1997) 40(101823–1828.
   Web of Science ®Google Scholar
• JACKSON CG, CLEGG DO: The seronegative spondylar-thropathies (Ankylosing spondylitis, Reiter's syndrome, psoriatic arthritis). In: Treatment of the Rheumatic Diseases. Weisman MH, Weinblatt ME (Eds.), Saunders, Philadelphia, USA (1995) :79–92.
   Google Scholar
• KHAN MA: Update: the twenty subtypes of HLA-B27. Curr. Opin. Rheumatol (2000) 12 (0235–238.
   PubMed Web of Science ®Google Scholar
• LITTLE H: The natural history of ankylosing spondy-litis. j Rheumatol. (1988) 15 (8) :1179–1180.
   PubMed Web of Science ®Google Scholar
• CALIN A, ELSWOOD J, RIGG S et al: Ankylosing spondy-litis: an analytical review of 1500 patients. The changing pattern of the disease. J. Rheumatol. (1988) 15 (8):1234–1238.
   PubMedGoogle Scholar
• GRAN JT, SKOMSVOLL JF: The outcome of ankylosingspondylitis: a study of 100 patients. Br. J. Rheumatol (1997) 36(7):766–771.
   PubMedGoogle Scholar
• •A retrospective study of the outcome of Norwegian AS patients.
   Google Scholar
• ROUSSOU E, KENNEDY LG, GARRETT S, CALIN A: Socioeconomic status in ankylo sing spondylitis: relationship between occupation and disease activity. Rheumatol. (1997) 24 (5) :908–911.
   Web of Science ®Google Scholar
• KHAN MA, KHAN MK, KUSHNER I: Survival among patients with ankylosing spondylitis: a life-table analysis. J. Rheumatol. (1981) 8(0:86–90.
   PubMedGoogle Scholar
• LEHTINEN K: Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondy-litis. Ann. Rheum. Dis. (1993) 52 (3) :174–176.
   PubMed Web of Science ®Google Scholar
• GRAN JT, HUSBY G: Ankylosing spondylitis. Current drug treatment. Drugs (1992) 44 (4):585–603.
   PubMed Web of Science ®Google Scholar
• ••A literature review of the drug treatment in AS, especially theNSAID usage.
   Google Scholar
• CUELLAR ML, ESPINOZA LR: Management of spondylar-thropathies. Curr. Opin. Rheumatol. (1996) 8 (4):288–295.
   PubMedGoogle Scholar
• TOUSSIROT E, WENDLING D: Current guidelines for the drug treatment of ankylosing spondylitis. Drugs (1998) 56 (2):225–240.
   PubMed Web of Science ®Google Scholar
• ••A recent literature review of the drug treatment in AS,including the second-line treatments.
   Google Scholar
• CALIN A, ELSWOOD J: A prospective nationwide cross-sectional study of NSAID usage in 1331 patients with ankylosing spondylitis. J. Rheumatol. (1990) 17 (6):801–803.
   PubMed Web of Science ®Google Scholar
• LAURENT R: Are there any antirheumatic drugs that modify the course of ankylosing spondylitis? BailBeres Rheumatol. (1990) 4(2):387–400.
   Google Scholar
• CREEMERS MCW, VAN RIEL PCLM, FRANSSEN MJAM: Second-line treatment in seronegative spondylarthro-pathies. Semin. Arthritis Rheum. (1994) 24(2) :71–81.
   PubMed Web of Science ®Google Scholar
• AMOR B, KAHAN A, DOUGADOS M et al: Sulfasalazineand ankylosing spondylitis. Ann. Intern. Med. (1984) 101 (6):878.
   PubMed Web of Science ®Google Scholar
• DOUGADOS M, BOUMIER P, AMOR B: Sulfasalazine in ankylosing spondylitis: a double blind placebo controlled study in 60 patients. Br. Med. J (1986) 293 (6552):911–914.
   PubMed Web of Science ®Google Scholar
• NISSILA M, LEHTINEN K, LEIRISALO-REPO M et al: Sulfasalazine in the treatment of ankylosing spondy-litis: a twenty-six-week, placebo-controlled clinical trial. Arthritis Rheum. (1988) 31 (9):1111–1116.
   PubMed Web of Science ®Google Scholar
• BOSI-FERRAZ M, TUGWELL P, GOLDSMITH C et al: Meta-analysis of sulfasalazine in ankylosing spondy-litis. Rheumatol. (1990) 17(10:1782–1786.
   Google Scholar
• ••A meta-analysis of the use and efficacy of sulfasalazine inAS.
   Google Scholar
• DOUGADOS M, VAN DER LINDEN S, LEIRISALO-REPO Met Sulfasalasine in the treatment of spondylarthro-pathy: a randomized, multicenter, double blind, placebo-controlled study. Arthritis Rheum. (1995) 3 8 (5):618–627.
   Google Scholar
• CLEGG DO, REDA DJ, WEISMAN MH et al.: Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. a Department of Veterans Affairs Cooperative Study. Arthritis Rheum. (1996) 39 (12):2004–2012.
   PubMed Web of Science ®Google Scholar
• CLEGG DO, REDA DJ, ABDELLATIF M: Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of seronega-tive spondylarthropathies. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. (1999) 42(10:2325–2329.
   PubMedGoogle Scholar
• •A study of the differential effects of sulfasalazine on axial and peripheral manifestations of spondylarthropathies based upon the analysis of a large controlled and random-ised trial involving 619 patients.
   Google Scholar
• MAUGARS Y, MATHIS C, BERTHELOT JM et al.: Assess- ment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double blind study. Br. J. Rheumatol. (1996) 35 (8):767–770.
   PubMedGoogle Scholar
• VANE J, BOTTING R: Mechanisms of action of anti-inflammatory drugs. In: Improved Non-Steroid Anti-Inflammatory Drugs COX-2 Enzyme Inhibitors. Vane J, Botting J, Boning R (Eds.), Kluwer Academic Publishers, Dordrecht, Netherlands (1996):1–29.
   Google Scholar
• NOBLE S, BALFOUR JA: Meloxicam. Drugs (1996) 51 (3):424–430.
   PubMed Web of Science ®Google Scholar
• FURST DE: Meloxicam: selective COX-2 inhibition in clinical practice. Semin. Arthritis Rheum. (1997) 26 (6):21–27.
   PubMed Web of Science ®Google Scholar
• DOUGADOS M, BEHIER J, JOLCHINE I et al.: Efficacy of celecoxib, a COX-2 specific inhibitor in ankylosing spondylitis: a placebo and conventional NSAID (ketoprofen) 6-week controlled study. Ann. Rheum. Dis. (2000) 59 (Suppl.):204–205.
   Google Scholar
• TAGGART A, GARDINER P, MCEVOY F, HOPKINS R, BIRD H: Which is the active moiety of sulfasalazine in ankylosing spondylitis? A randomized, controlled study. Arthritis Rheum. (1996) 3 9 (8) :1400–1405.
   Google Scholar
• DEKKER-SAEYS BJ, DIJKMANS BAC, TYTGAT GNJ: Treatment of sp on dylarthrop athy with 5-aminosalicylic acid (mesalazine): an open trial. J Rheumatol. (2000) 27(3):723–726.
   PubMed Web of Science ®Google Scholar
• THOMSON GTD, THOMSON BRJ, THOMSON KS, DUCHARME JS: Clinical efficacy of mesalamine in the treatment of sp on dylarthr op athies. j Rheumatol. (2000) 27 (3):714–718.
   PubMed Web of Science ®Google Scholar
• HANDLER R: Favorable results using methotrexate in the treatment of patients with ankylosing spondylitis. Arthritis Rheum. (1989) 32(2):234.
   PubMed Web of Science ®Google Scholar
• BOSI-FERRAZ M, CARRICO DA, SILVA H et al: LOW dose methotrexate with leucovorin rescue in ankylosing spondylitis. j Rheumatol. (1991) 18(0:146–147.
   Google Scholar
• TOUSSIROT E, WENDLING D: L'utilisation du methotrexate dans les spondylarthropthies: revue de la litterature. Rev. Med. Intern. (1996) 1 7 (0333–339.
   Web of Science ®Google Scholar
• SAMPAIO-BARROS PD, COSTALLAT LTL, FERNANDES SRM et al.: The use of methotrexate in the treatment of ankylosing spondylitis: pilot study. Rev. Esp. Rheumatol. (1993) 20 (Suppl.):485.
   Google Scholar
• CREEMERS MCW, FRANSEN MJAM, VAN DE PUTTE LBA et Methotrexate in severe ankylosing spondylitis: an open study. J Rheumatol. (1995) 22(6):1104–1107.
   PubMed Web of Science ®Google Scholar
• OSTENDORF B, SPECKER C, SCHNEIDER M: Ankylosing spondylitis: clinical and serological response to methotrexate therapy compared with rheumatoid arthritis. Arthritis Rheum. (1995) 38 (Suppl.) :S203.
   Google Scholar
• BIASI D, CARLETTO A, CAAMASCHI P, PACOR ML, MALEKNIA T, BAMBARA LM: Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clin. Rheumatol. (2000) 1 9 (2):114–117.
   Google Scholar
• •A recent open study of methotrexate therapy in AS with a long-term follow-up.
   Google Scholar
• MAKSYMOWYCH WP, JHANGRI GS, LECLERCQ S, SKEITH K, YAN A, RUSSEL AS: An open study of pamidronate in the treatment of refractory ankylosing spondylitis. Rheumatol. (1998) 25 (4) :714–717.
   Web of Science ®Google Scholar
• •The first open study of pamidronate in AS patients giving favourable results on axial symptoms.
   Google Scholar
• GARRETT S, JENKINSON T, WHITELOCK H et al: A new approach to defining disease status in AS: the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). j Rheumatol. (1994) 21 (12) :2286–2291.
   PubMed Web of Science ®Google Scholar
• CALIN A, GARRETT S, WHITELOCK H et al: A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Sp ondylitis Functional Index (BASFT). J. Rheumatol. (1994) 21 (12):2281–2285.
   PubMed Web of Science ®Google Scholar
• JENKINSON TR, MALLORIE TA, WHITELOCK H et al: Defining spinal mobility in ankylosing spondylitis (AS): the Bath Ankylosing Spondylitis Metrology Index (BASMI). j Rheumatol. (1994) 21 (9) :1694–1698.
   PubMed Web of Science ®Google Scholar
• MAKSYMOWYCH WP, LECLERCQ S, JHANGRI GS et al: A randomized double-blinded response comparison of intravenous pamidronate in the treatment of NSAID refractory ankylosing spondylitis. Arthritis Rheum. (1999) 42(9) (Suppl.):S376.
   Google Scholar
• TOUSSIROT E, WENDLING D: Bone mass in ankylosing spondylitis. Olin. Exp. Rheumatol. (2000) 18 (Suppl. 21):516–20.
   Google Scholar
• CORRAL L, KAPLAN G: immunomodulation by thalido-mide and thalidomide analogues. Ann. Rheum. Dis. (1999) 58 (Suppl. D:1107–1113.
   Google Scholar
• WENDLING D, TOUSSIROT E, MICHEL F: Thalidomide: a come-back? Joint Bone Spine (2000) 67 (4):259–261.
   PubMedGoogle Scholar
• BREBAN M, GOMBERT B, AMOR B, DOUGADOS M: Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis. Arthritis Rheum. (1999) 42 (3) :580–581.
   PubMed Web of Science ®Google Scholar
• •A report of two patients giving the favourable effects of thalidomide in the treatment of severe refractory AS.
   Google Scholar
• MCCREDIE J, WILLERT HG: longitudinal limb deficien-cies and the sclerotomes. An analysis of 378 dysmelic malformations induced by thalidomide. J. Bone Joint Surg. Br. (1999) 81(0:9–23.
   Google Scholar
• BRAUN J, SIEPER J: Anti-TNFa: a new dimension in the pharmacotherapy of spondylarthropathies? Ann. Rheum. Dis. (2000) 59 (6):404–406.
   PubMed Web of Science ®Google Scholar
• GRATACOS J, COLLADO A, FILELLA X et al: Serum cytokines (IL-6, TNF-a, IL-113 and IFNy) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br. J. Rheumatol (1994) 33(10):927–931.
   PubMedGoogle Scholar
• BRANDT J, HAIBEL H, CORNELY D et al: Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor-a monoclonal antibody infliximab. Arthritis Rheum. (2000) 43 (6) :1346–1352.
   PubMed Web of Science ®Google Scholar
• •The first study to report the dramatic improvement of AS patients with refractory and severe disease with the mAb infliximab, suggesting the potential use of this biological agent and additionally, the involvement of TNF-a in AS pathophysiology.
   Google Scholar
• VAN DER BOSCH F, KRUITHOF E, BAETEN D, DE KEYSER F, MIELANTS H, VEYS EM: Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumor necrosis factor-a (infliximab) in spondylarthropathy: an open pilot study. Ann. Rheum. Dis. (2000) 59(6):428–433.
   PubMed Web of Science ®Google Scholar
• ••A second open study with infliximab confirming the resultsby Brandt et al. and extending the treatment to the other spondylarthropathies (psoriatic arthritis and undifferenti-ated spondylarthropathy).
   Google Scholar